MTSR vs PEPG vs ARWR vs VKTX vs AMGN

For growth investors, Arrowhead Pharmaceuticals, Inc.

(ARWR) is the stronger pick with 232. 6% revenue growth year-over-year, versus 9. 9% for Amgen Inc. (AMGN). Amgen Inc. (AMGN) offers the better valuation at 23. 6x trailing P/E (15. 0x forward), making it the more compelling value choice. Analysts rate Metsera, Inc. (MTSR) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Viking Therapeutics, Inc.

(VKTX) delivered a total return of +429. 1%, compared to -87. 0% for PepGen Inc. (PEPG). Over 10 years, the gap is even starker: VKTX returned +24. 7% versus PEPG's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), PepGen Inc.

(PEPG) is the lower-risk stock at -0. 10β versus Arrowhead Pharmaceuticals, Inc. 's 1. 74β — meaning ARWR is approximately -1889% more volatile than PEPG relative to the S&P 500. On balance sheet safety, Viking Therapeutics, Inc. (VKTX) carries a lower debt/equity ratio of 0% versus 6% for Amgen Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arrowhead Pharmaceuticals, Inc.

(ARWR) is pulling ahead at 232. 6% versus 9. 9% for Amgen Inc. (AMGN). On earnings-per-share growth, the picture is similar: Arrowhead Pharmaceuticals, Inc. grew EPS 99. 8% year-over-year, compared to -215. 8% for Viking Therapeutics, Inc.. Over a 3-year CAGR, ARWR leads at 50. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Amgen Inc.

(AMGN) is the more profitable company, earning 21. 0% net margin versus -0. 2% for Arrowhead Pharmaceuticals, Inc. — meaning it keeps 21. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMGN leads at 29. 1% versus 0. 0% for VKTX. At the gross margin level — before operating expenses — ARWR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for PEPG: 316.

7% to $7. 00.

In this comparison, AMGN (2.

8% yield) pays a dividend. MTSR, PEPG, ARWR, VKTX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Amgen Inc.

(AMGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 61), 2. 8% yield, +165. 4% 10Y return). Viking Therapeutics, Inc. (VKTX) carries a higher beta of 1. 54 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AMGN: +165. 4%, VKTX: +24. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: MTSR is a small-cap quality compounder stock; PEPG is a small-cap quality compounder stock; ARWR is a mid-cap high-growth stock; VKTX is a small-cap quality compounder stock; AMGN is a mid-cap quality compounder stock. AMGN pays a dividend while MTSR, PEPG, ARWR, VKTX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.